Loading
NASDAQHealthcareBiotechnology
Latest quote
$2.11
+$0.08 · +3.94%
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The company is developing T cell-based test technologies intended to support an immunology profiling platform, with potential applications in post-acute infection syndromes, including Long COVID, and other chronic conditions linked to immune dysregulation.
Previous close
$2.11
+$0.08 · +3.94%
Pre-market
$2.0201
−$0.0899 · -4.26%
Oct 8, 8:22 AM ET
Regular session · ET · Market data may be delayed.
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The company is developing T cell-based test technologies intended to support an immunology profiling platform, with potential applications in post-acute infection syndromes, including Long COVID, and other chronic conditions linked to immune dysregulation.
Day range
Current $2.11
52-week range
Current $2.11
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
74
Undervalued
Sentiment
49
Mixed
Risk
71
High Risk
Momentum
26
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The company is developing T cell-based test technologies intended to support an immunology profiling platform, with potential applications in post-acute infection syndromes, including Long COVID, and other chronic conditions linked to immune dysregulation.
Day range
Current $2.11
52-week range
Current $2.11
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | 12.42K USD | 6.33K USD | 156.42K USD | 8.56K USD | — |
| Cost of goods sold | 4.73K USD | 59.4K USD | 105.83K USD | 9.93K USD | — |
| Gross profit | 7.69K USD | −53.07K USD | 50.59K USD | −1.37K USD | — |
| Research and development | 3.74M USD | 1.78M USD | 1.56M USD | 397.11K USD | 433.74K USD |
| Selling, general, and administrative | 2.67M USD | 4.33M USD | 4.59M USD | 5.33M USD | 1.3M USD |
| Operating expenses | 6.41M USD | 6.11M USD | 6.55M USD | 5.73M USD | 1.73M USD |
| Interest expense | 61.77K USD | 58.18K USD | 26.88K USD | 15.47K USD | 15.44K USD |
| Depreciation and amortization | 439.02K USD | 343.39K USD | 103.1K USD | 1 USD | 1.73M USD |
| Operating income | −6.4M USD | −6.16M USD | −6.5M USD | −5.73M USD | −1.73M USD |
| Net income | −5.02M USD | −6.06M USD | −6.73M USD | −5.46M USD | −1.71M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
